Global Oral Solid Dosage CDMO Market Revenue Grows at a CAGR of 6.56%.

Straits Research released its highly anticipated report, “Global Oral Solid Dosage CDMO Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 45.98 billion in 2025 and is anticipated to grow till USD 81.17 billion by 2034, growing at a CAGR of 6.56% from 2026-2034.

Market Dynamics

The oral solid dosage CDMO market is driven by the sustained expansion of oral drug pipelines across chronic therapies, where tablets and capsules remain the preferred administration route due to dosing convenience and patient adherence. Pharmaceutical companies increasingly outsource formulation development, scale-up, and commercial manufacturing to external partners to manage portfolio breadth, accelerate timelines, and reduce fixed infrastructure burden. However, the market faces restraint from complexity associated with transferring formulations across development and manufacturing stages, particularly for modified release and high potency products, where process sensitivity and equipment variability affect reproducibility. Regulatory scrutiny across global supply chains further increases coordination challenges for sponsors and CDMOs. Despite these constraints, a strong opportunity exists in the rising demand for specialized CDMOs with expertise in controlled release technologies, containment manufacturing, and integrated packaging solutions. Growth in lifecycle management activities such as reformulations, line extensions, and regional product adaptations supports long-term outsourcing engagement, positioning oral solid dosage CDMOs as strategic partners rather than transactional manufacturers.

Market Highlights

• Product: Based on Product, the tablets segment dominated the market with a revenue share of 33.45% in 2025.
• Mechanism: Based on the Mechanism, controlled release dominated the market with a revenue share of 44.56% in 2025.
• Drug Potency: Based on Drug Potency, low-potency drugs dominated the market with a revenue share of 34.67%.
• Service: Based on Service, contract development dominated the market with a revenue share of 23.45%.
• End Use: Based on End Use, medium & small companies dominated the market with 44.56%.
• Regional Insights: North America held a dominant share of the global market, accounting for 37.54% in 2025.

Market Segments

1. By Product (2026-2034)
   1. Tablets
      1. Compressed Tablets
      2. Orally Disintegrating Tablets (ODT)
      3. Chewable Tablets
      4. Bi-layer or Tri-layer Tablets
      5. Sublingual or Buccal Tablets
      6. Others
   2. Capsules
      1. Hard Gelatin Capsules
      2. Soft Gelatin Capsules
   3. Powders
   4. Granules
   5. Others
2. By Mechanism (2026-2034)
   1. Immediate Release
   2. Delayed Release
   3. Controlled Release
3. By Drug Potency (2026-2034)
   1. High Potent Drugs
   2. Moderate Potent Drugs
   3. Low Potent Drugs
4. By Service (2026-2034)
   1. Contract Development
   2. Contract Manufacturing
   3. Packaging and Labelling
   4. Regulatory Affairs
   5. Logistics & Storage
   6. Others
5. By End Use (2026-2034)
   1. Large Size Companies
   2. Medium & Small Size Companies
   3. Others